Fanny Jaulin emphasizes that successful drug trials are crucial, stating, 'Just because a drug isn't successful in clinical trials doesn't mean it's not a good drug.' This reflects the complexities inherent in cancer treatment.
Orakl Oncology differentiates itself by combining data with biological insights, creating a hybrid model, where Jaulin notes, 'The data side helps deal with the fact that each tumor is unique, while the biology side is the best way to take the complexity of cancer into account.'
Jaulin acknowledges that AI is becoming essential in drug discovery, saying, 'AI is becoming table stakes in drug discovery,' highlighting the competitive landscape that emerging companies must navigate.
With their focus on colorectal and pancreatic cancers, Orakl aims to offer two key products, O-Predict and O-Validate, designed to enhance drug development and patient response prediction.
Collection
[
|
...
]